非小细胞肺癌临床实践指南（2015 年第 6 版）

Non-Small Cell Lung Cancer, Version 6.2015.

机构信息

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Washington/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; City of Hope Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Stanford Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Mayo Clinic Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

出版信息

J Natl Compr Canc Netw. 2015 May;13(5):515-24. doi: 10.6004/jnccn.2015.0071.

DOI:10.6004/jnccn.2015.0071

PMID:25964637

Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

摘要

这些 NCCN 指南解读重点介绍了 2015 年 NCCN 非小细胞肺癌（NSCLC）指南的最新更新。对于晚期 NSCLC 患者，适当的靶向治疗非常有效，这些患者具有特定的遗传改变。因此，对晚期 NSCLC 患者的肿瘤组织进行检测，以确定他们是否存在使他们成为特定靶向治疗候选者的遗传改变非常重要。这些 NCCN 指南解读描述了目前可用于确定患者是否存在两种最常见的可操作遗传改变（间变性淋巴瘤激酶（ALK）基因重排和敏感表皮生长因子受体（EGFR）突变）的不同检测方法。